Poolbeg Pharma

POLB · AIM · Health Care · mcap £46m · 6.4p

Poolbeg develops medicines for cancer immunotherapy-induced cytokine release syndrome (POLB 001) and an oral GLP-1 delivery technology for obesity. It aims to partner or commercialise these assets and holds patents and FDA Orphan Drug Designation for POLB 001.

Target	Promise	Said	Status
2024
2024	Complete lab validation of AI-identified influenza drug targets	26 Oct 2023	⏱ Overdue – no update
	“lab-based validation, which is expected to complete in 2024” Status so far The deadline has passed; no announcement since says whether it was met. We check again as new reports come in.
2025
2025-04	Continue due diligence on Behçet's disease drug during 12-month option	30 Apr 2024	✗ Missed
	“Poolbeg will continue due diligence throughout the term of the exclusive option agreement which will include engagement with Silk Road Therapeutics to ascertain the clinical approval pathway” Result No later card mentions exercising the option or the Behçet's asset; pipeline now centres on POLB 001 and GLP-1.
H2 2025	Dose first patient in POLB 001 Phase 2a trial in H2 2025	20 May 2025	✗ Missed
	“First patient dosed is expected in H2 2025 and Phase 2a topline data is expected in H2 2026” Also stated 20 May 2025 How it developed 20 May 2025 Said “The anticipated Phase 2a trial commencement is targeted for H2 2025, with topline data expected to be available in H2 2026” 20 May 2025 Said “First patient dosed is expected in H2 2025 and Phase 2a topline data is expected in H2 2026” 13 Jul 2026 ✗ Missed “13 July 2026 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company with a core focus on transforming the...” Result MHRA authorisation came April 2026 and first patient was dosed in July 2026, after the H2 2025 target. “13 July 2026 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, today announces that the first patient has been dosed in the POLB 001 TOPICAL clinical trial.”13 Jul 2026 · First patient dosed in POLB 001 TOPICAL trial
Today · 2 Nov 2026
2026
H2 2026	Start oral GLP-1 proof-of-concept trial (first 2024, later H1 2026 data, now start in H2 2026)	30 Apr 2024	✗ Missed · target changed
	“commencement of oral GLP-1 proof-of-concept trial at University of Ulster, led by Prof Carel le Roux with up to 20 obese subjects, now expected to commence in H2 2026” Also stated 18 Sep 2024 · 28 Apr 2026 · 29 Sep 2026 How it developed 30 Apr 2024 Said “working towards commencement of its proof-of-technology clinical trial in 2024” 18 Sep 2024 Said “proof-of-technology clinical trial in late 2024 to demonstrate the successful delivery of an oral GLP-1R agonist in humans” 20 May 2025 ↻ Changed / dropped “We continued to progress our oral encapsulated glucagon-like peptide ("GLP-1") programme towards a proof of concept trial that is expected to deliver...” 28 Apr 2026 Said “commencement of oral GLP-1 proof-of-concept trial at University of Ulster, led by Prof Carel le Roux with up to 20 obese subjects, now expected to commence...” 29 Sep 2026 Said “the proof-of-concept clinical study, which is expected to commence in H2 2026” Result Start slipped from 2024 to H2 2026; topline data guidance of H1 2026 was dropped. Trial not yet started at September 2026. “We continued to progress our oral encapsulated glucagon-like peptide ("GLP-1") programme towards a proof of concept trial that is expected to deliver topline data in H1 2026.”20 May 2025 · Results for the year ended 31 December 2024
late summer 2026	Deliver POLB 001 Phase 2a (TOPICAL) interim data, now guided to late summer 2026 (earlier H1 2026 interim, H2 2026 topline)	2 Jan 2025	✗ Missed · target changed
	“Phase 2a topline data for POLB 001 in the second half of 2026” Also stated 27 May 2025 · 25 Sep 2025 · 11 Jun 2026 · 13 Jul 2026 How it developed 2 Jan 2025 Said “Phase 2a topline data for POLB 001 in the second half of 2026” 27 May 2025 Said “interim analysis expected in H1 2026” 25 Sep 2025 ↻ Changed / dropped “interim data anticipated in summer 2026” 25 Sep 2025 Said “interim data anticipated in summer 2026” 11 Jun 2026 Said “we look forward to sharing interim data from the TOPICAL trial in multiple myeloma patients later this summer” 13 Jul 2026 Said “Interim data remains on track for late summer 2026” 13 Jul 2026 ↻ Changed / dropped “Interim data remains on track for late summer 2026” Result Interim analysis moved from H1 2026 to summer, then late summer 2026; still on track in July 2026 but not yet delivered. “interim data anticipated in summer 2026”25 Sep 2025 · POLB 001 Phase 2a Trial Update “Interim data remains on track for late summer 2026”13 Jul 2026 · First patient dosed in POLB 001 TOPICAL trial
H1 2026	HOOKIPA combination: HB-700 Phase 1 interim data H1 2026, HB-500 Phase 1b primary completion H2 2025, completion early Q2 2025	2 Jan 2025	✗ Missed · target changed
	“Phase 1 interim data for HB-700 in the first half of 2026” How it developed 2 Jan 2025 Said “Phase 1 interim data for HB-700 in the first half of 2026” 20 Feb 2025 ↻ Changed / dropped “the HOOKIPA Board has determined that it does not intend to make an offer for Poolbeg under Rule 2.7 of the Code.” 21 Feb 2025 ↻ Changed / dropped “HOOKIPA has terminated discussions on the proposed combination of the two companies.” Result HOOKIPA said it would not make an offer in February 2025 and terminated discussions; the combination did not happen. “the HOOKIPA Board has determined that it does not intend to make an offer for Poolbeg under Rule 2.7 of the Code.”20 Feb 2025 · HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”) “HOOKIPA has terminated discussions on the proposed combination of the two companies.”21 Feb 2025 · Termination of proposed combination with HOOKIPA
2028
Q2 2028	Cash runway into 2027, later extended into Q2 2028 after July 2026 placing	20 May 2025	✗ Missed · target changed
	“the net proceeds of the Placing, together with Poolbeg's existing resources, are expected to extend the Company's cash runway into Q2 2028” Also stated 14 Jul 2026 How it developed 20 May 2025 Said “providing financial runway into 2027” 14 Jul 2026 Said “the net proceeds of the Placing, together with Poolbeg's existing resources, are expected to extend the Company's cash runway into Q2 2028” 14 Jul 2026 ↻ Changed / dropped “The net proceeds of the Placing, together with Poolbeg's existing resources, are expected to extend the Company's cash runway into Q2 2028.” 29 Sep 2026 ↻ Changed / dropped “Following the successful £3.5 million (before expenses) fundraising completed in July 2026, we strengthened our balance sheet and extended our cash runway...” Result Runway into 2027 was extended to Q2 2028 by a £3.5m placing at 6p in July 2026; cash was £4.8m at June 2026. “The net proceeds of the Placing, together with Poolbeg's existing resources, are expected to extend the Company's cash runway into Q2 2028.”14 Jul 2026 · Placing to raise £3.5 million “Following the successful £3.5 million (before expenses) fundraising completed in July 2026, we strengthened our balance sheet and extended our cash runway into Q2 2028.”29 Sep 2026 · Half-year Results
Q2 2028	Fund TOPICAL and oral GLP-1 proof-of-concept trials through to completion	14 Jul 2026	… In progress
	“funds both the POLB 001 TOPICAL trial and the oral GLP-1 proof-of-concept trial through to completion and extends the cash runway into Q2 2028” Status so far Not yet due.